Latest ISN iNET-CKD study on hypertension now available in KIiclaron
Kidney International (KI) is pleased to announce the publication of a study on hypertension, led by the ISN iNET-CKD (International Network of chronic kidney disease cohort studies). This study highlights considerable international variation in hypertension control and treatment in chronic kidney disease (CKD).
The new study from the ISN iNET-CKD highlights substantial variation in the prevalence of uncontrolled blood pressure (BP) and in antihypertensive prescription in CKD.
The study includes more than 34,000 participants from 17 cohort studies worldwide. Read the full article HERE.
In addition, the study also revealed regional patterns of antihypertensive prescription, including a higher number of therapy classes among North American cohorts than elsewhere. It also demonstrated a preference for calcium-channel blockers, rather than diuretics, as the second choice therapy in Asian cohorts.
Consistent with current recommendations, RAAS inhibitors were the most-prescribed drugs in all studied settings. BP control achievement, however, was insufficient. Only 16-46% of participants had BP lower than 130/80 mm Hg, according to cohorts.
With increasing evidence of the potential benefits of even lower BP targets, findings from the iNET-CKD study highlight the need for further investigation into real-life approaches to BP management in CKD.
You can find out more about iNET-CKD here.